PATENT CLAIM ANALYSIS

Application Number: 15935010
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "143100"]

Abstract:
A method of treating triple negative breast cancer in a subject comprising administering to the subject a therapeutically effective amount of a combination of at least two anti epidermal growth factor receptor (EGF-R) antibodies exhibiting binding to different epitopes on the EGF-R, thereby treating triple negative breast cancer.

Claim (Index 2):
The method of  claim 1 , wherein said first anti-EGFR antibody and said second anti-EGFR antibody comprise full length antibodies.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 90.0
- Lexical Diversity: 1.33333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14118243', '14956585', '13641174', '13061417', '14536754']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7469930635147893
- 35 USC 102 Novelty (BERT): 0.5507364115583999
- Combined Prediction Score: 0.7273673983191504
- Mean Citation Score: 366.390904
- Max Citation Score: 401.58322
- Similarity Product: 299.23414721697446

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test